Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1403-1406

  Cassaday, Ryan D ^a,b   Guthrie, Katherine A ^a   Budde, Elizabeth L ^a,b   Thompson, Leslie ^a,b   Till, Brian G ^a,b   Press, Oliver W ^a,b   Chauncey, Thomas R ^a,b,c   Pagel, John M ^a,b   Petersdorf, Stephen H ^a,b   Palanca Wessels, Maria Corinna ^a,b   Philip, Mary ^a,b   Bensinger, William I ^a,b   Holmberg, Leona A ^a,b   Shustov, Andrei ^a,b   Green, Damian J ^a,b   Libby, Edward N ^a,b   Maloney, David G ^a,b   Gopal, Ajay K ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Autologous transplantation; Mantle cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SCORING SYSTEM; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; REMISSION; TUMOR RECURRENCE;

ADULT; AGED; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84882746664     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.07.005     Document Type: Article

References (19)

1. Dreyling M., Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009, 542-551.
2. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. JClin Oncol 2009, 27:511-518.
3. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
4. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with invivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
5. Damon L.E., Johnson J.L., Niedzwiecki D., et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. JClin Oncol 2009, 27:6101-6108.
6. Le Gouill S., Callanan M., Macintyre E., et al. Clinical, metabolic and molecular responses after four courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study. Blood 2012, 120. (ASH Annual Meeting Abstracts) Abstract 152.
7. Hermine O., Hoster E., Walewski J., et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2012, 120. (ASH Annual Meeting Abstracts) Abstract 151.
8. Delarue R., Haioun C., Ribrag V., et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013, 121:48-53.
9. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. JClin Oncol 1998, 16:13-18.
10. Vose J.M., Bierman P.J., Weisenburger D.D., et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000, 6:640-645.
11. Till B.G., Gooley T.A., Crawford N., et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008, 49:1062-1073.
12. Hoster E., Dreyling M., Klapper W., et al. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
13. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. JClin Oncol 2007, 25:579-586.
14. Fenske T.S., Carreras J., Zhang M., et al. Outcome of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. Ann Oncol 2011, (11th International Conference on Malignant Lymphoma) Abstract 18.
15. Cohen J.B., Hall N., Ruppert A.S., et al. The prognostic value of FDG PET/CT prior to autologous stem cell transplant in mantle cell lymphoma. Blood 2011, 118. (ASH Annual Meeting Abstracts) Abstract 3113.
16. Gressin R., Caulet-Maugendre S., Deconinck E., et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010, 95:1350-1357.
17. Touzeau C., Delarue R., Leux C., et al. Autologous stem cell transplantation in mantle cell lymphoma: The experience of the French SFGM-TC group. Blood 2010, 116. (ASH Annual Meeting Abstracts) Abstract 2392.
18. Kluin-Nelemans H.C., Hoster E., Hermine O., et al. Treatment of older patients with mantle-cell lymphoma. NEngl J Med 2012, 367:520-531.
19. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013, 10.1016/S0140-6736(12) 61763-2.